BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO • US0905722072
256.56 USD
-35.86 (-12.26%)
At close: Feb 13, 2026
256.56 USD
0 (0%)
After Hours: 2/13/2026, 8:04:00 PM
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- BIO had positive earnings in the past year.
- BIO had a positive operating cash flow in the past year.
- BIO had negative earnings in 4 of the past 5 years.
- Of the past 5 years BIO 4 years had a positive operating cash flow.
1.2 Ratios
- BIO has a Return On Assets of -6.97%. This is comparable to the rest of the industry: BIO outperforms 53.45% of its industry peers.
- BIO has a Return On Equity (-10.03%) which is comparable to the rest of the industry.
- With a decent Return On Invested Capital value of 2.26%, BIO is doing good in the industry, outperforming 62.07% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 12.42%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- The Operating Margin of BIO (10.27%) is better than 70.69% of its industry peers.
- In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
- Looking at the Gross Margin, with a value of 52.42%, BIO is in the better half of the industry, outperforming 63.79% of the companies in the same industry.
- BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
- BIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- BIO has an Altman-Z score of 3.12. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of BIO (3.12) is better than 68.97% of its industry peers.
- The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
- BIO has a Debt to FCF ratio of 3.57. This is in the better half of the industry: BIO outperforms 77.59% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
- BIO has a Debt to Equity ratio (0.18) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.12 |
ROIC/WACC0.22
WACC10.41%
2.3 Liquidity
- A Current Ratio of 5.44 indicates that BIO has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 5.44, BIO belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
- A Quick Ratio of 3.94 indicates that BIO has no problem at all paying its short term obligations.
- The Quick ratio of BIO (3.94) is better than 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- BIO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.19% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
3.2 Future
- The Earnings Per Share is expected to decrease by -2.38% on average over the next years.
- Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 1.57% on average per year.
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue Next Year2.23%
Revenue Next 2Y2.93%
Revenue Next 3Y1.34%
Revenue Next 5Y1.57%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 25.86 indicates a quite expensive valuation of BIO.
- 68.97% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.97. BIO is around the same levels.
- A Price/Forward Earnings ratio of 25.03 indicates a quite expensive valuation of BIO.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 72.41% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (27.96), we can say BIO is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.86 | ||
| Fwd PE | 25.03 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 82.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.55 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
- BIO's earnings are expected to decrease with -3.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)7.76
PEG (5Y)N/A
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
5. Dividend
5.1 Amount
- No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
256.56
-35.86 (-12.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners92.92%
Inst Owner Change-0.17%
Ins Owners8.18%
Ins Owner Change0%
Market Cap6.92B
Revenue(TTM)N/A
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (41.14%)
Short Float %4.33%
Short Ratio4.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-4.14%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.86 | ||
| Fwd PE | 25.03 | ||
| P/S | 2.71 | ||
| P/FCF | 20.55 | ||
| P/OCF | 14.08 | ||
| P/B | 1.03 | ||
| P/tB | 1.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.87%
EPS(NY)10.25
Fwd EY4%
FCF(TTM)12.48
FCFY4.87%
OCF(TTM)18.22
OCFY7.1%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)7.76
PEG (5Y)N/A
Graham Number236.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.12 |
F-Score5
WACC10.41%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
Revenue Next Year2.23%
Revenue Next 2Y2.93%
Revenue Next 3Y1.34%
Revenue Next 5Y1.57%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 3.33% in the next year.